Skip to main content
Premium Trial:

Request an Annual Quote

NCI Grants BioMarker Strategies SBIR Funds

NEW YORK (GenomeWeb News) – BioMarker Strategies, a molecular diagnostics developer focused on tumor testing, has won a Small Business Innovation Research grant from the National Cancer Institute.

The Fast-Track SBIR grant gives the company an initial award of $254,000, a number that could increase by up to $2 million after the initial phase of the work is completed, the firm said.

The company plans to use the funds to "expedite production" of a prototype of its SnapPath live-tumor cell testing system, BioMarker Strategies CEO Karen Olson said in a statement.

Based in the Johns Hopkins Science and Technology Park in Baltimore, Md., BioMarker Strategies also is developing a series of pathway-based ex-vivo biomarker tests to guide targeted cancer therapeutics.

The Scan

Less Than Half

An effort to reproduce key findings from high-profile preclinical cancer studies finds less than half could be replicated, according to the Scientist.

Still Some SARS-CoV-2 Sequencing Holes

The Wall Street Journal reports that viral genomic surveillance has improved in the US, though says there are still gaps.

Avoiding Passing Them On

People with known disease-linked genetic variants are turning to in vitro fertilization so as to not pass those variants to their children, the Washington Post says.

PNAS Papers on Long Cell-Free DNA in Maternal Plasma, Genetic Propensity for Voting

In PNAS this week: long, cell-free DNA of maternal and fetal origins identified in maternal plasma, and more.